- $249.73m
- -$38.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 0.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -103.68% | ||
| Return on Equity | -198.66% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alumis Inc. is a clinical-stage biopharmaceutical company. The Company is developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases, such as monotherapy or combination therapies. It is focused on developing its two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. Its ESK-001 is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 29th, 2021
- Public Since
- June 28th, 2024
- No. of Employees
- 168
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 54,407,327
- Address
- 280 East Grand Avenue, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.alumis.com/
- Phone
- +1 6502316625
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ALMS
Similar to ALMS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Alumis share price?
As of Today at 19:13 UTC, shares in Alumis are trading at $4.59. This share price information is delayed by 15 minutes.
How has the Alumis share price performed this year?
Shares in Alumis last closed at $4.59 and the price had moved by over the past 365 days. In terms of relative price strength the Alumis share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Alumis?
The overall consensus recommendation for Alumis is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Alumis dividend yield?
Alumis does not currently pay a dividend.
Does Alumis pay a dividend?
Alumis does not currently pay a dividend.
When does Alumis next pay dividends?
Alumis does not currently pay a dividend.
How do I buy Alumis shares?
To buy shares in Alumis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alumis?
As of the previous close price of $4.59, shares in Alumis had a market capitalisation of $249.73m.
Where are Alumis shares listed?
Here are the trading details for Alumis:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALMS
What kind of share is Alumis?
Based on an overall assessment of its quality, value and momentum Alumis is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alumis share price forecast for 2025?
The analyst consensus target price for shares in Alumis is $21.50. That is 368.41% above the last closing price of $4.59.
Analysts covering Alumis currently have a consensus Earnings Per Share (EPS) forecast of -$4.12 for the next financial year.
Find out moreWhat is the trend in the Alumis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alumis. Over the past six months, its share price has underperformed the S&P500 Index by -59.23%.
As of the last closing price of $4.59, shares in Alumis were trading -48.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alumis PE Ratio?
The Alumis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alumis?
We do not have data on Alumis' directors